Tag: PVOTF

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Continues to Advance its Agenda

  • Owns worldwide rights for patented formulations and drug delivery technologies
  • Develops and commercializes therapeutic pharmaceuticals and nutraceuticals
  • Strategic agenda to become one of world’s only vertically integrated cannabis biotechs

With worldwide rights for unique drug delivery platforms in place, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is rapidly building a disruptive, vertically integrated biotechnology company. Advancing this agenda, the company recently announced that it has retained Cannabis Compliance Inc. to submit an application to Health Canada for a dealer’s license on behalf of Pivot’s acquisition target, Agro-Biotech Inc. (http://cnw.fm/0K5Xn).

In February, Pivot announced that its entry into a letter of intent for the proposed acquisition of licensed cannabis producer Agro-Biotech (http://cnw.fm/cvP6W), which operates a fully licensed indoor hydroponic cannabis production facility that’s on track to expand its capacity 10,000 kg per year by the end of this year. Upon completion of the proposed acquisition, the dealer’s license will enable Pivot (through Agro-Biotech) to conduct research and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations.

With the acquisition of Agro-Biotech, Pivot Pharmaceuticals will control the entire manufacturing process from seed to medical derivatives and capture margins along the entire supply chain. The dealer’s license will move Pivot another step closer to becoming one of the only vertically integrated cannabis biotech companies in the world. Pivot is already a differentiated player in the Canadian cannabis industry with its unique approach to enhanced dosing and bioavailability of cannabinoids, and the company’s position in the market will only be bolstered by the acquisition.

Pivot Pharmaceuticals has assembled cutting-edge drug delivery technologies that assist both effectiveness and efficacy of medicinal cannabinoids and have potential applications across other drug categories. Pivot’s patent pending topical transdermal drug delivery technology platform, BiPhasix™, has been shown to significantly enhance the bioavailability of various drugs, leading to improved clinical outcomes. The company also acquired worldwide rights to Solmic Solubilisation Technology Platform, which allows active ingredients to become water-soluble without changing their composition or nature, significantly enhancing drug uptake.

With proven pharmaceutical and patented formulation and delivery technologies, Pivot is well positioned in an important, growing vertical of the cannabis industry and represents a compelling opportunity in the biotechnology sector. This latest announcement by Pivot enhances the opportunity.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Finding Ever-Growing Ways to Administer Cannabis Benefits

  • Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets
  • Company’s goal is to strengthen dosage predictability and improve product stability
  • Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries

Despite recent setbacks to efforts seeking broader marijuana legalization in North America (http://cnw.fm/zM2Mc), the tide of social preferences for cannabis availability, even in recreational applications, continues to advance (http://cnw.fm/tT62e). Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is helping to advance efforts to legitimize the drug’s use, both in medicinal and recreational settings, by pursuing ever-increasing methods for consuming cannabis’s derivatives in quantities with predictable outcomes.

“Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” Joseph Borovsky, Pivot’s vice president of product formulation, stated in a recent news release (http://cnw.fm/ji5nV).

The company has filed continuation patents to maintain its impetus in making cannabis available through powdered formulations that can be combined with existing products in the food and beverage market. That includes health and wellness products such as natural sleep-aids, cold medications and vitamins.

On March 6, Pivot Pharmaceuticals announced its acquisition of Thrudermic, LLC, a North Carolina company invested in a transdermal lipid-based nano-dispersion technology to make cannabis formulations available through external delivery. Thrudermic has filed three new patent applications for Pivot related to better formulation and delivery of its product as the company pursues new routes of drug administration.

Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption.

“The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market,” Pivot CEO Patrick Frankham stated in a news release about the acquisition (http://cnw.fm/1xDEK).

The company has also announced plans to acquire Agro-Biotech, a Quebec-based Canadian-licensed cannabis producer (http://cnw.fm/av6uC). Agro-Biotech operates a licensed hydroponic cannabis production facility that can turn out 10,000 kilograms per year, giving Pivot a source for its products as it strives to achieve a stronger vertical position in the industry for cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC).

An agreement between Pivot and Germany’s Solmic Research GmbH gave the company rights to technology designed to give cancer patients relief from vomiting, nausea, neutropenia and anemia during chemotherapy treatment. Those side effects trouble an estimated 70 to 80 percent of chemotherapy patients and often lead to the discontinuation of treatment before the illness has been completely addressed, according to Transparency Market Research (http://cnw.fm/1N15u). Cannabis’s therapeutic abilities are expected to help it grow into a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/F3jWv), and the cancer supportive care products market is expected to reach $29.87 billion by 2021.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Advances CBD Therapy Delivery Options

  • Forecasts envision medical cannabis market reaching $55.8 billion by 2025
  • PVOTF filing patents for smoked, transdermal and mucosal delivery of therapeutics
  • Global partnerships and acquisitions open windows of opportunity for company

With its recently announced plan to acquire Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/WPwl2), Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) has raised the bar in the race to capture part of the booming medical cannabis market, which is expected to reach over $55 billion by 2025. Agro-Biotech, which operates a fully-licensed indoor hydroponic cannabis production facility that’s able to turn out 10,000 kilograms per year, gives Pivot Pharmaceuticals a unique vertically-integrated position in the industry. Pivot is already known for its advanced patent-backed CBD therapy delivery options, and delivery technology has become a hot button in the burgeoning marijuana market.

Amid the flurry of activity surrounding the rush to provide medical marijuana therapies in markets where it is newly legalized, one lingering question regulators and industry insiders continue to grapple with is how to best administer cannabis to patients seeking relief from muscle spasms, pain, anxiety and other disorders. Pivot Pharmaceuticals is evaluating and preparing to market a variety of drug delivery technologies that can help the assimilation of cannabinoids for such human and veterinary patients.

Pivot has identified an area of need within the industry as efforts to provide clinical data for cannabis’s purported benefits strive to establish a scientific credence to what has been a largely word-of-mouth substantiation of the drug. Decades of recreational use, mostly in smoking marijuana, as well as historical research into cannabis’s ancient therapeutic uses, have given rise to the newly popular movement to establish clinical uses for the plant as governmental recognition has spread across the United States and Canada, as well as in some other countries across the globe.

As part of that movement, some companies are searching for alternatives to smoking the plant, not only to avoid the image of casual and medically unregulated recreational drug use but also out of concern for patients’ health and the interests of non-patients who may be offended by the smoke. Pivot has filed three provisional patents targeting different cannabinoid delivery methods. One anticipates inhalation for delivery of the therapeutics, another promotes transdermal passage through the skin using patches and creams, and a third prefers topical delivery through mucus in the buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository (http://cnw.fm/qT4N3).

The British Columbia, Canada-based company’s agreement with Germany’s Solmic Research GmbH has given Pivot worldwide rights to the Solmic Solubilisation technology underpinning a water-soluble oral solution that Pivot has made ready for market. A partnership with Israel’s Solubest Ltd. has resulted in a semi-solid cream that is currently in the stability evaluation phase of development, and Pivot’s anticipated February 28 closing on its option to acquire 100 percent of North Carolina’s Thrudermic, LLC has already led to the commencement of development of a product using Thrudermic’s transdermal nanotechnology for a systemic cannabidiol (CBD) product. Access to Israeli labs licensed to work with CBD and its more intoxicating cannabis sibling tetrahydrocannabinol (THC) gives Pivot an edge in research and development.

Pivot is also scheduled to close on its acquisition of California’s ERS Holdings, LLC on February 28, which has a patented ready-to-infuse cannabis (“RTIC”) oil-to-powder technology that Pivot expects to monetize by entering the cannabis-infused beverage market, particularly in the alcohol beverage industry, where Pivot has already identified potential partners as beverage companies battle the possibility of legal marijuana eating into beer sales (http://cnw.fm/AdR47). The company also expects to use RTIC technology for wellness products such as over-the-counter sleep aids and cough medications.

As legalization has spread for cannabis’s medical applications, market forecasts have grown, and the therapeutic product derivatives of the plant are expected to fuel a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/98vNG). Pivot’s first Solmic-enabled oral product, PGS-N001, is designed to provide relief to patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia — major side effects from cancer treatment that often lead to the premature discontinuation of the treatment. Of the 14 million new cancer diagnoses identified by the National Cancer Institute in 2012, about four million of them were expected to lead to chemotherapy treatment, and chemotherapy-induced nausea and vomiting (“CINV”) affects an estimated 70 to 80 percent of patients undergoing chemotherapy, according to Transparency Market Research (http://cnw.fm/8RC0y), fueling a cancer supportive care products market that’s expected to reach $29.87 billion by 2021.

Pivot intends to register PGS-N001 as a natural health product for consumers and follow it with other products that will have a shorter development cycle as they follow the natural health product pathway.

“Solmic’s water-soluble technology has already been demonstrated in the nutraceutical and cosmeceutical markets in Europe,” Pivot CEO Patrick Frankham stated in a news release. “The addition of Solmic, our second disruptive drug delivery technology platform for cannabinoids, strengthens our business strategy to be a market leader in the development and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.”

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) “Seed to Derivatives” – Vertical Integration in Burgeoning Cannabis Market

  • Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives”
  • Development and commercialization of therapeutic pharmaceuticals and nutraceuticals
  • Patented formulation and delivery technologies

Scientific studies have provided empirical credence to the medical efficacy of cannabinoids for multiple maladies. Globally, researchers and biopharmaceutical companies are now laser focused on cannabinoid-based therapeutics that may hold blockbuster medical potential, providing solutions to a range of unmet medical needs. However, current drug delivery techniques remain antiquated. There are inherent metabolic and bioavailability issues affecting the consistent, effective delivery of cannabinoids. It’s becoming clear that these new pharmaceutical therapeutics require revolutionary delivery techniques.  Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is establishing new paradigms in cannabinoid drug development and delivery.

Pivot Pharmaceuticals is transforming the development and commercialization of these new therapeutic pharmaceuticals and nutraceuticals with unique drug delivery platform technologies. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals, and it has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical) and Solmic Solubilisation technology (oral) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. The company recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office (http://cnw.fm/2e8HS), and these latest patent filings join an established number of global rights to topical, oral, transdermal, food and beverage technologies that Pivot has already secured.

Pivot’s pipeline of potential CBD-based pharmaceuticals now covers treatment indications for supportive care to relieve nausea, mucositis and pain, including cancer-related and menstrual pain, dermatological conditions and even glaucoma. Pivot is also developing and commercializing an array of pharmaceutical-grade formulations for cannabinoid-based consumer health care products.

With enhanced drug delivery and development well underway, Pivot has turned to its next business objective, vertical integration. The company just announced a Letter of Intent for the proposed acquisition of Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/rGD5M). Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility capable of producing a cumulative 10,000 kilograms per year.

Pivot is already a differentiated player in the Canadian cannabis industry due to its unique approach to enhanced dosing and bioavailability of cannabinoids with proven pharmaceutical and patented formulation and delivery systems. With the acquisition of Agro-Biotech, Pivot Pharmaceuticals expects to become vertically integrated, controlling the entire manufacturing process from “seed to derivatives” and capturing margin along the entire supply chain.

In the news release, Dr. Patrick Frankham, Pivot CEO, stated, “I am delighted to welcome Agro-Biotech to Pivot…  With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization.  Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway.  After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives.  Pivot will only work with partners who truly control their processes and have the finest infrastructure and qualified personnel.  We believe that these characteristics will define best in class products for wellness and health conscious consumers using bio-cannabis….”

This latest announcement follows a pattern of strong corporate development by Pivot Pharmaceuticals and uniquely positons the company to become a major force in the burgeoning cannabis markets not only in Canada but around the world.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (PVOTF) Provides Update Covering Recent Achievements and Activities

  • Update highlights proposed acquisitions, product development and growing IP portfolio
  • Three new patent filings join established global rights to other patented technologies
  • Innovative transdermal delivery technology increases bioavailability of cannabinoids
  • Global cannabis market projected to reach $31.4 billion by 2021

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://cnw.fm/sB649). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”

Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://cnw.fm/8Kg16).

As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://cnw.fm/J3CsB) issued on February 1, 2018.  Its three patents cover:

  • Transdermal nanotechnology delivery of cannabis using patches and creams
  • Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
  • Inhalation delivery of cannabis for topic or systemic applications

These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.

A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.

Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.

In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.

The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.

Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (PVOTF) is “One to Watch”

  • Transdermal cannabis-based therapy promises greater absorption, less side effects
  • Global medical marijuana market projected to reach $55.8 billion U.S. by 2025
  • Novel CBD delivery method targets array of unmet healthcare needs

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net